JP2023546140A5 - - Google Patents
Info
- Publication number
- JP2023546140A5 JP2023546140A5 JP2023523099A JP2023523099A JP2023546140A5 JP 2023546140 A5 JP2023546140 A5 JP 2023546140A5 JP 2023523099 A JP2023523099 A JP 2023523099A JP 2023523099 A JP2023523099 A JP 2023523099A JP 2023546140 A5 JP2023546140 A5 JP 2023546140A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2016425.7A GB202016425D0 (en) | 2020-10-16 | 2020-10-16 | Treatment regimens for parkinson's disease |
| GB2016425.7 | 2020-10-16 | ||
| PCT/PT2021/050036 WO2022081033A1 (en) | 2020-10-16 | 2021-10-14 | Opicapone and levodopa for the treatment of parkinson's disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023546140A JP2023546140A (ja) | 2023-11-01 |
| JPWO2022081033A5 JPWO2022081033A5 (https=) | 2024-10-11 |
| JP2023546140A5 true JP2023546140A5 (https=) | 2024-10-11 |
Family
ID=73598546
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023523099A Pending JP2023546140A (ja) | 2020-10-16 | 2021-10-14 | パーキンソン病の治療のためのオピカポン及びレボドパ |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230398105A1 (https=) |
| EP (1) | EP4228618A1 (https=) |
| JP (1) | JP2023546140A (https=) |
| KR (1) | KR20230088753A (https=) |
| CN (1) | CN116490171A (https=) |
| AU (1) | AU2021360114A1 (https=) |
| GB (1) | GB202016425D0 (https=) |
| WO (1) | WO2022081033A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3860603A1 (en) | 2018-10-05 | 2021-08-11 | Neurocrine Biosciences, Inc. | Methods for the administration of comt inhibitors |
| JP2024500754A (ja) * | 2020-12-17 | 2024-01-10 | ビアル－ポルテラ エ コンパニア，ソシエダッド アノニマ | 早期特発性パーキンソン病のための治療レジメン |
| GB202212082D0 (en) * | 2022-08-18 | 2022-10-05 | Bial Portela & Ca Sa | Treatment regimens for parkinson's disease |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110002462A (ko) | 2008-03-17 | 2011-01-07 | 바이알 - 포르텔라 앤드 씨에이 에스에이 | 5-[3-(2,5-디클로로-4,6-디메틸-1-옥시-피리딘-3-일)-[1,2,4]옥사디아졸-5-일]-3-나이트로벤젠-1,2-디올의 결정형 |
| AU2010231961B2 (en) | 2009-04-01 | 2015-05-21 | Bial - Portela & Ca., S.A. | Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof |
| RU2550133C2 (ru) | 2009-04-01 | 2015-05-10 | БИАЛ-ПОРТЕЛА энд КА., С.А. | Фармацевтические составы, включающие производные нитрокатехола, и способы их получения |
| US20140045900A1 (en) * | 2011-02-11 | 2014-02-13 | Bial-Portela & Ca, S.A. | Administration regime for nitrocatechols |
| WO2013089573A1 (en) | 2011-12-13 | 2013-06-20 | BIAL - PORTELA & Cª., S.A. | Chemical compound useful as intermediate for preparing a catechol-o-methyltransferase inhibitor |
| JP2018500300A (ja) * | 2014-11-28 | 2018-01-11 | ノヴィファーマ，エス．アー． | パーキンソン病を遅延させるための医薬 |
| RU2018110580A (ru) * | 2015-08-27 | 2019-09-30 | Прекстон Терапьютикс Са | Проникающее в мозг производное оксима хромона для терапии леводопа-индуцированной дискинезии |
| MX383906B (es) * | 2015-10-09 | 2025-03-14 | Teva Pharmaceuticals Int Gmbh | Combinación de levodopa deuterado con carbidopa y opicapona para el tratamiento del mal de parkinson |
| JP2020023540A (ja) * | 2019-10-11 | 2020-02-13 | ノヴィファーマ，エス．アー． | パーキンソン病を遅延させるための医薬 |
-
2020
- 2020-10-16 GB GBGB2016425.7A patent/GB202016425D0/en not_active Ceased
-
2021
- 2021-10-14 WO PCT/PT2021/050036 patent/WO2022081033A1/en not_active Ceased
- 2021-10-14 JP JP2023523099A patent/JP2023546140A/ja active Pending
- 2021-10-14 KR KR1020237016045A patent/KR20230088753A/ko active Pending
- 2021-10-14 EP EP21801249.0A patent/EP4228618A1/en active Pending
- 2021-10-14 CN CN202180077619.0A patent/CN116490171A/zh active Pending
- 2021-10-14 AU AU2021360114A patent/AU2021360114A1/en active Pending
- 2021-10-14 US US18/032,034 patent/US20230398105A1/en active Pending